Company: GRCE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001140361-25-041804
Chunk: 14

Company: Grace Therapeutics, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Item 8
Chunk 14
---
, the organizational and reporting structure and the type of information reviewed by the CODM to allocate resources and evaluate financial performance.
   
   The Company has one reportable operating segment: the development and commercialization of pharmaceutical applications of its patents and licensed rights. The Company’s CODM is its Chief Executive Officer. The accounting policies of the segment are those described in the summary of significant accounting policies.  
  
   The CODM assesses the performance of the segment based on net loss, which is reported on the unaudited condensed consolidated statement of net loss and comprehensive loss as Net loss and total comprehensive loss. The measure of segment assets is reported on the unaudited condensed consolidated balance sheet as Total assets.

   The Company has not generated any revenue and expects to continue to incur significant expenses and operating losses as it advances product candidates through all stages of development, and ultimately, receive regulatory approval. Accordingly, the CODM utilizes the cash budget and forecasts in assessing the entity-wide operating results and performance, and in deciding how to allocate resources across the organization and its segment. Net loss and total comprehensive loss is used to monitor budgets against actual results, which then is used in assessing the performance of the segment.

  18
  

 The table below summarizes the significant expenses, by category regularly reviewed by the CODM, for the three and six months ended September 30, 2025 and 2024:  

     Three months ended
     
      Six months ended

      September 30, 2025

      September 30, 2024

      September 30, 2025

      September 30, 2024

      $ 
       $ 
      $ 
      $ 

      Clinical development programs
     
      81 
      2,662 
      527 
      5,067 

      Professional fees
     
      1,104 
      981 
      2,092 
      2,475 

      Salaries and benefits
     
      760 
      728 
      1,562 
      1,330 

      Stock-based compensation
     
      204 
      202 
      507 
      440 

      Other general and administrative expenses (1)
     
      380 
      267 
      931 
     491

      Other segment  income (2)